AUSTIN: The North American consortium, Alzheimer’s Disease Cooperative Study (ADCS), recently completed a phase II clinical trial to test the efficiency of a novel drug T-817MA (Chemical Name: 1-{3-[2-(1-benzothiophen-5-yl)ethoxy] propyl}-3-azetidinol maleate). Researchers at Clinical Trials of Texas (CTT) and the University of North Texas Health Science Center (UNTHSC) have reported their findings…